Immunohistochemical and Histochemical Studies of Β-Cells Insulin Up-Regulation in Pancreatic Tissues of Streptozotocin-Induced Diabetic Albino Rats Treated with Melatonin and Magnesium

Background: Improve insulin secretion and cellular availability to reduced blood glucose levels in diabetic subjects by bioactive compound especially antioxidants are the new focus to ameliorate the complication with diabetes mellitus. Aims and objectives: The aim of this study was to evaluate the effects of administration of melatonin and magnesium on the cytoarchitecture of the pancreatic tissue and to access immunohistochemically insulin release in streptozotocin-induced diabetic Albino rats. Materials and methods: To achieve this aim six normoglycaemic rats and fourty eight Streptozotocin (STZ) induced diabetic rats was used in the study after two weeks acclimatization period. The animals were assigned into nine groups as follows, Normal control group (NC), Diabetic control (DC) group, Melatonin at 10 mg/kgb (MLD), magnesium dose group of 240 mg/kgbw (MgLD), melatonin and magnesium combined group of 10mg/kgbw+240mg/kgbw (MMgLD), melatonin group of 20mg/kgbw (MHD), melatonin and magnesium high dose combined group of 20mg/kgbw+480mg/kgbw (MMgHD) and insulin at 500mg/kgbw group (IN). Melatonin and insulin were administered through intraperitoneal injections (IP) while magnesium was by oral administration. The control groups were given placebo and all groups’ treatment was for twenty-one days. At the end of the study, the animals were aestheticized and euthanized to harvest pancreatic organ. The organs were fixed in neutral buffered formaldehyde (NBF). They were histologically prepared and stained using haematoxylin and eosin and immunohistochemically stained using insulin antibody to access insulin release. Results: Melatonin treatment at 10mg/kgbw and at 20 mg/kgbw showed histological improvement in histological tissues and insulin release while when combined with magnesium at dose of 10mg/kgbw and at 240 mg/kgbw showed better results. The administration of magnesium at 240 mg/kgbw, 480 mg/kgbw and when combined with melatonin at high doses does not show significant improvement in islet β-cell proliferation and insulin release. Conclusion: The administration of melatonin and magnesium at low doses regenerates pancreatic islet histoarchitecture and augments insulin release from treated diabetic albino rats.

[1]  Srishti Singh,et al.  Protective Role of Melatonin in Streptozotocin Induced Pancreatic Damages in Diabetic Wistar Rat. , 2018, Pakistan journal of biological sciences : PJBS.

[2]  Brenda C T Kieboom,et al.  Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population , 2018, Pharmacoepidemiology and drug safety.

[3]  Jingjing Wang,et al.  Oxidative Stress in Pancreatic Beta Cell Regeneration , 2017, Oxidative medicine and cellular longevity.

[4]  E. Saber,et al.  Effect of Platelet Rich Plasma (PRP) Injection on the Endocrine Pancreas of the Experimentally Induced Diabetes in Male Albino Rats: A Histological and Immunohistochemical Study , 2017 .

[5]  Ting Wang,et al.  Effect of sophora japonica total flavonoids on pancreas, kidney tissue morphology of streptozotocin-induced diabetic mice model , 2017, Saudi journal of biological sciences.

[6]  R. Reiter,et al.  Melatonin as an antioxidant: under promises but over delivers , 2016, Journal of pineal research.

[7]  M. Dominici,et al.  Cell therapies for pancreatic beta-cell replenishment , 2016, Italian Journal of Pediatrics.

[8]  M. A. Mohd,et al.  Extract of Woodfordia fruticosa flowers ameliorates hyperglycemia, oxidative stress and improves β-cell function in streptozotocin-nicotinamide induced diabetic rats. , 2015, Journal of ethnopharmacology.

[9]  M. Barbagallo,et al.  Magnesium and Type 2 Diabetes: An Update , 2015 .

[10]  Srinivasan Ar,et al.  SERUM magnesium levels as an indicator of status of Diabetes Mellitus type 2. , 2015, Diabetes & metabolic syndrome.

[11]  N. A. Muraleva,et al.  Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[12]  O. IbegbuA.,et al.  Hypoglycaemic effects of melatonin and ethanol extract of Azadirachta indica administration on blood glucose levels in streptozotocin-induced diabetic Wistar rats , 2014 .

[13]  David Whiting,et al.  The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. , 2011, Diabetes research and clinical practice.

[14]  V. Londhey,et al.  Hypomagnesemia in critically ill medical patients. , 2011, The Journal of the Association of Physicians of India.

[15]  G. Tosini,et al.  Removal of Melatonin Receptor Type 1 Induces Insulin Resistance in the Mouse , 2010, Obesity.

[16]  D. Jacobs,et al.  Magnesium Intake in Relation to Systemic Inflammation, Insulin Resistance, and the Incidence of Diabetes , 2010, Diabetes Care.

[17]  M. Jarvelin,et al.  G-allele of Intronic rs10830963 in MTNR1B Confers Increased Risk of Impaired Fasting Glycemia and Type 2 Diabetes Through an Impaired Glucose-Stimulated Insulin Release , 2009, Diabetes.

[18]  L. Groop,et al.  A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals , 2009, Diabetologia.

[19]  Beverley,et al.  The G-allele of intronic rs 10830963 in MTNR 1 B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release : studies involving 19 , 605 Europeans , 2009 .

[20]  M. Somei,et al.  Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases , 2008, Journal of pineal research.

[21]  Elmar Peschke,et al.  Melatonin, endocrine pancreas and diabetes , 2007, Journal of pineal research.

[22]  M. Schulze,et al.  Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. , 2007, Archives of internal medicine.

[23]  M. Barbagallo,et al.  Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. , 2007, Archives of biochemistry and biophysics.

[24]  I. Kang,et al.  Melatonin stimulates glucose transport via insulin receptor substrate‐1/phosphatidylinositol 3‐kinase pathway in C2C12 murine skeletal muscle cells , 2006, Journal of pineal research.

[25]  G. Ferry,et al.  Molecular tools to study melatonin pathways and actions. , 2005, Trends in pharmacological sciences.

[26]  J. Miller,et al.  Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. , 2005, Clinical nephrology.

[27]  G. Paolisso,et al.  Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man , 1986, Diabetologia.

[28]  M. Barbagallo,et al.  Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. , 2003, Molecular aspects of medicine.

[29]  M. Dubocovich,et al.  MT(2) melatonin receptors are present and functional in rat caudal artery. , 2002, The Journal of pharmacology and experimental therapeutics.

[30]  L Brydon,et al.  Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. , 2001, Endocrinology.

[31]  R. Reiter,et al.  Actions of Melatonin in the Reduction of Oxidative Stress , 2000, Journal of Biomedical Science.

[32]  A. Sandvik,et al.  The diffuse neuroendocrine system and extrapineal melatonin. , 1997, Journal of molecular endocrinology.

[33]  M. Barbagallo,et al.  Cellular Ions in NIDDM: Relation of Calcium to Hyperglycemia and Cardiac Mass , 1996, Diabetes Care.

[34]  J. Sheehan.  Magnesium deficiency and diabetes mellitus. , 1991, Magnesium and trace elements.

[35]  C. Duarte.  Effects of chlorothiazide and amipramizide (MK 870) on the renal excretion of calcium, phosphate and magnesium. , 1968, Metabolism: clinical and experimental.